Company: IMRX
Filing Date: 2025-09-25
Form Type: 8-K
Source: 0001104659-25-093436
Chunk: 0

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into a Material Definitive Agreement.

On September 24, 2025, Immuneering Corporation (the “ Company”)
entered into an underwriting agreement (the “ Underwriting Agreement”) with Leerink Partners LLC and Oppenheimer & Co.
Inc., as underwriters (the “ Underwriters”), in connection with the public offering, issuance and sale by the Company of 18,959,914
shares of the Company’s Class A common stock, at a public offering price of $9.23 per share, pursuant to an effective shelf registration
statement on Form S-3 (Registration No. 333-289589) and a related prospectus supplement filed with the Securities and Exchange Commission
(the “ Offering”). In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriters an option,
exercisable for a period of 30 days, to purchase up to an additional 2,843,987 shares of Class A common stock from the Company, less underwriting
discounts and commissions. All of the shares of Class A common stock to be sold in the Offering are being sold by the Company.

In addition, as previously disclosed by the Company in a Current
Report on Form 8-K filed with the Securities and Exchange Commission on September 24, 2025, the Company entered into a securities
purchase agreement, dated September 24, 2025 (the “ Purchase Agreement”), with Aventis Inc. (the “ Investor”),
a wholly owned subsidiary of Sanofi, a French société anonyme, pursuant to which the Company, in a private placement
transaction (the “ Private Placement”), agreed to issue and sell to the Investor $25.0 million of shares of Class A
common stock (or in certain circumstances in lieu of Class A common stock, shares of the Company’s non-voting Class B common
stock), subject to and contingent upon the closing of a firm commitment underwritten public offering of Class A common stock by the
Company that results in gross proceeds to the Company of at least $75.0 million and the pricing of which is publicly announced in a
press release issued by the Company on or before September 26, 2025 (a “ Qualified Public Offering”). Pursuant to the
Purchase Agreement, the price per share in the Private Placement will be the price per share of Class A common stock to the public
in the Qualified Public Offering. Under the terms of the Purchase Agreement, the Offering